Birdwatch Note
2024-02-20 17:24:16 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
レプリコンワクチンとは新型コロナウイルスSタンパク受容体結合ドメイン（RBD）を細胞膜上に発現させるmRNAワクチンです 全く別のワクチンの様に紹介されている事に留意が必要です https://prtimes.jp/main/html/rd/p/000000002.000118477.html レプリコンワクチンは日本において第Ⅲ相臨床試験を通過しています chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.meiji-seika-pharma.co.jp/pressrelease/2023/detail/pdf/230929_01.pdf chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.meiji-seika-pharma.co.jp/pressrelease/2023/detail/pdf/231128_02.pdf https://www3.nhk.or.jp/news/html/20231128/k10014271431000.html 不確かな噂に惑わされず信頼できる情報源から情報収集に努めましょう https://www.cov19-vaccine.mhlw.go.jp/qa/0075.html https://togetter.com/li/2195650 https://togetter.com/li/2176345 https://togetter.com/li/2174198
Written by 7A9FF9E0AC22B46DA9E28988C69E88AB84BA7BDC51EFDA1B44D021A9037A2442
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1759943436919001233
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1759992377530561026
- noteId - 1759992377530561026
- participantId -
- noteAuthorParticipantId - 7A9FF9E0AC22B46DA9E28988C69E88AB84BA7BDC51EFDA1B44D021A9037A2442 Participant Details
- createdAtMillis - 1708449856539
- tweetId - 1759943436919001233
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 1
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- レプリコンワクチンとは新型コロナウイルスSタンパク受容体結合ドメイン（RBD）を細胞膜上に発現させるmRNAワクチンです 全く別のワクチンの様に紹介されている事に留意が必要です https://prtimes.jp/main/html/rd/p/000000002.000118477.html レプリコンワクチンは日本において第Ⅲ相臨床試験を通過しています chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.meiji-seika-pharma.co.jp/pressrelease/2023/detail/pdf/230929_01.pdf chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.meiji-seika-pharma.co.jp/pressrelease/2023/detail/pdf/231128_02.pdf https://www3.nhk.or.jp/news/html/20231128/k10014271431000.html 不確かな噂に惑わされず信頼できる情報源から情報収集に努めましょう https://www.cov19-vaccine.mhlw.go.jp/qa/0075.html https://togetter.com/li/2195650 https://togetter.com/li/2176345 https://togetter.com/li/2174198
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-02-20 17:24:16 UTC (1708449856539) |
2024-02-21 04:10:14 UTC (1708488614531) |
CURRENTLY_RATED_HELPFUL | 2024-02-21 09:05:56 UTC (1708506356169) |
NEEDS_MORE_RATINGS | 2024-02-21 04:10:14 UTC (1708488614531) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-02-20 19:23:06 -0600 | Rating Details | |
| 2024-02-20 16:44:33 -0600 | Rating Details | |
| 2024-02-20 16:08:46 -0600 | Rating Details | |
| 2024-02-20 15:50:24 -0600 | Rating Details | |
| 2024-02-20 15:40:31 -0600 | Rating Details | |
| 2024-02-20 15:39:59 -0600 | Rating Details | |
| 2024-02-20 15:32:51 -0600 | Rating Details | |
| 2024-02-20 15:30:31 -0600 | Rating Details | |
| 2024-02-20 11:53:41 -0600 | Rating Details | |
| 2024-02-20 11:53:23 -0600 | Rating Details | |
| 2024-02-20 11:44:40 -0600 | Rating Details | |
| 2024-02-21 06:00:56 -0600 | Rating Details | |
| 2024-02-21 05:54:35 -0600 | Rating Details | |
| 2024-02-21 05:29:09 -0600 | Rating Details | |
| 2024-02-21 04:38:14 -0600 | Rating Details | |
| 2024-02-21 04:04:51 -0600 | Rating Details | |
| 2024-02-22 18:41:44 -0600 | Rating Details | |
| 2024-02-21 06:08:20 -0600 | Rating Details | |
| 2024-02-21 04:53:42 -0600 | Rating Details | |
| 2024-02-21 04:28:13 -0600 | Rating Details | |
| 2024-02-21 03:36:08 -0600 | Rating Details | |
| 2024-02-21 03:01:47 -0600 | Rating Details | |
| 2024-02-21 02:47:58 -0600 | Rating Details | |
| 2024-02-21 02:14:15 -0600 | Rating Details | |
| 2024-02-21 02:00:56 -0600 | Rating Details | |
| 2024-02-21 00:53:01 -0600 | Rating Details | |
| 2024-02-21 00:44:47 -0600 | Rating Details | |
| 2024-02-21 00:09:31 -0600 | Rating Details | |
| 2024-02-21 00:03:15 -0600 | Rating Details | |
| 2024-02-21 00:00:20 -0600 | Rating Details | |
| 2024-02-20 21:50:55 -0600 | Rating Details | |
| 2024-02-20 21:48:15 -0600 | Rating Details | |
| 2024-02-20 20:23:44 -0600 | Rating Details | |
| 2024-02-20 18:06:26 -0600 | Rating Details | |
| 2024-02-20 16:42:49 -0600 | Rating Details | |
| 2024-02-20 16:27:17 -0600 | Rating Details | |
| 2024-02-20 14:14:20 -0600 | Rating Details | |
| 2024-02-20 11:49:22 -0600 | Rating Details | |
| 2024-02-22 03:59:37 -0600 | Rating Details | |
| 2024-02-22 03:53:08 -0600 | Rating Details | |
| 2024-02-21 06:34:16 -0600 | Rating Details | |
| 2024-02-21 06:14:47 -0600 | Rating Details | |
| 2024-02-21 06:10:30 -0600 | Rating Details | |
| 2024-02-21 03:49:33 -0600 | Rating Details | |
| 2024-02-21 02:37:31 -0600 | Rating Details | |
| 2024-02-21 00:24:51 -0600 | Rating Details | |
| 2024-02-21 00:23:13 -0600 | Rating Details | |
| 2024-02-20 22:40:01 -0600 | Rating Details | |
| 2024-02-20 18:53:31 -0600 | Rating Details | |
| 2024-02-20 18:40:34 -0600 | Rating Details | |
| 2024-02-20 18:10:38 -0600 | Rating Details | |
| 2024-02-20 17:40:36 -0600 | Rating Details | |
| 2024-02-20 17:36:42 -0600 | Rating Details | |
| 2024-02-20 16:34:41 -0600 | Rating Details | |
| 2024-02-20 16:32:42 -0600 | Rating Details | |
| 2024-02-20 16:26:08 -0600 | Rating Details | |
| 2024-02-20 16:23:22 -0600 | Rating Details | |
| 2024-02-20 16:13:41 -0600 | Rating Details | |
| 2024-02-20 16:01:29 -0600 | Rating Details | |
| 2024-02-20 15:46:21 -0600 | Rating Details | |
| 2024-02-20 15:19:38 -0600 | Rating Details | |
| 2024-02-20 15:16:11 -0600 | Rating Details | |
| 2024-02-20 15:01:07 -0600 | Rating Details | |
| 2024-02-20 12:49:11 -0600 | Rating Details |